Adaptation and validation of the Cambridge pulmonary hypertension outcome review for Sweden

Scandinavian Journal of Public Health

Volumn 40, Issue 8, 2012, Pages 777-783

  Selimovic, Nedim ^a   Rundqvist, Bengt ^a   Kjörk, Ewa ^a   Viriden, Johan ^b   Twiss, James ^c   Mckenna, Stephen P ^c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Actelion Pharmaceuticals Sverige AB   (Sweden)

^c GALEN RESEARCH   (United Kingdom)

Author keywords

adaptation; health status; pulmonary hypertension; Quality of life; questionnaire; validity

Indexed keywords

ADULT; AGED; ARTICLE; DAILY LIFE ACTIVITY; FEMALE; HUMAN; LANGUAGE; MALE; METHODOLOGY; MIDDLE AGED; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; PULMONARY HYPERTENSION; QUALITY OF LIFE; QUESTIONNAIRE; REPRODUCIBILITY; SELF EVALUATION; SEVERITY OF ILLNESS INDEX; SWEDEN;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; DIAGNOSTIC SELF EVALUATION; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; SWEDEN; TRANSLATING; YOUNG ADULT;

EID: 84870606556     PISSN: 14034948     EISSN: 16511905     Source Type: Journal    
DOI: 10.1177/1403494812464445     Document Type: Article

References (20)

1. Rubin L.J. Primary pulmonary hypertension. N Engl J Med 1997;336(2):111–7.
2. Rubin L.J. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(1 Suppl):7S–10S.
3. Robin E.D. The kingdom of the near-dead. The shortened unnatural life history of primary pulmonary hypertension. Chest 1987;92(2):330–4.
4. D'Alonzo G.E. Barst R.J. Ayres S.M. Bergofsky E.H. Brundage B.H. Detre K.M. et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115(5):343–9.
5. Galie N. Palazzini M. Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010;31(17): 2080–6.
6. Sitbon O. Humbert M. Nunes H. Parent F. Garcia G. Herve P. et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40(4):780–8.
7. McLaughlin V.V. Shillington A. Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106(12):1477–82.
8. Barst R.J. Galie N. Naeije R. Simonneau G. Jeffs R. Arneson C. et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006;28(6):1195–203.
9. Hoeper M.M. Oudiz R.J. Peacock A. Tapson V.F. Haworth S.G. Frost A.E. et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004;43(12 Suppl):48S–55S.
10. McKenna S.P. Doughty N. Meads D.M. Doward L.C. Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006;15(1):103–15.
11. Hunt S.M. McEwen J. McKenna S.P. Measuring health status: a new tool for clinicians and epidemiologists. J R Coll Gen Pract 1985;35(273):185–8.
12. Andrich D. Rasch models for measurement. SAGE Publications, 1988.
13. Hunt S.M. McKenna S.P. The QLDS: a scale for the measurement of quality of life in depression. Health Policy 1992;22(3):307–19.
14. Bennet S.J. Oldridge N.B. Eckert G.J. Embree J.L. Browning S. Hou N. et al. Discriminant properties of commonly used quality of life measures in heart failure. Qual Life Res 2002;11(4):349–59.
15. Coffin D. Duval K. Martel S. Granton J. Lefebvre M.C. Meads D.M. et al. Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Can Respir J 2008;15(2):77–83.
16. Gomberg-Maitland M. Thenappan T. Rizvi K. Chandra S. Meads D.M. McKenna S.P. United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant 2008;27(1):124–30.
17. Ganderton L. Jenkins S. McKenna S.P. Gain K. Fowler R. Twiss J. et al. Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology 2011;16(8):1235–40.
18. Hunt S.M. Alonso J. Bucquet D. Niero M. Wiklund I. McKenna S. Cross-cultural adaptation of health measures. European Group for Health Management and Quality of Life Assessment. Health Policy 1991;19(1):33–44.
19. Hedin P.J. McKenna S.P. Meads D.M. The Rheumatoid Arthritis Quality of Life (RAQo) for Sweden: adaptation and validation. Scand J Rheumatol 2006;35(2): 117–23.
20. Zlupko M. Harhay M.O. Gallop R. Shin J. Archer-Chicko C. Patel R. et al. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med 2008;102(10):1431–8.